Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.3% – Here’s What Happened

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) shot up 7.3% during trading on Friday . The company traded as high as $14.04 and last traded at $14.04. 3,674,520 shares traded hands during trading, a decline of 31% from the average session volume of 5,364,061 shares. The stock had previously closed at $13.09.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across multiple periods, including FY2026, signaling a modestly improved outlook for Intellia Therapeutics.
• Positive Sentiment: The firm kept a Buy rating and $25 price target, reinforcing bullish sentiment after recent first-quarter results. Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright
• Neutral Sentiment: Other recent coverage, including Hold ratings from Wells Fargo and Wedbush, suggests overall analyst opinion remains mixed despite the upbeat HC Wainwright revisions. Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
• Negative Sentiment: Even after the estimate increases, Intellia is still expected to report losses for 2026 and 2027, reflecting ongoing profitability concerns.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. reiterated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. Canaccord Genuity Group dropped their price objective on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, March 2nd. Finally, KeyCorp set a $25.00 target price on Intellia Therapeutics in a report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Stock Up 3.7%

The firm’s fifty day simple moving average is $13.64 and its 200-day simple moving average is $11.98. The company has a market cap of $1.90 billion, a PE ratio of -3.85 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. During the same period in the previous year, the firm posted ($1.10) EPS. On average, analysts predict that Intellia Therapeutics, Inc. will post -3.37 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NTLA. AQR Capital Management LLC lifted its holdings in Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics in the first quarter valued at approximately $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after buying an additional 38,521 shares during the period. Creative Planning lifted its stake in shares of Intellia Therapeutics by 12.9% during the second quarter. Creative Planning now owns 33,102 shares of the company’s stock valued at $310,000 after buying an additional 3,795 shares during the period. Finally, Cetera Investment Advisers boosted its position in Intellia Therapeutics by 47.4% during the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after acquiring an additional 10,785 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.